Published in Clin Exp Immunol on August 01, 2003
The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease. Clin Chim Acta (2007) 1.14
[Secondary vasculitides and vasculitis mimics]. Z Rheumatol (2012) 0.77
Genetic variations of TAP1 gene exon 3 affects gene expression and Escherichia coli F18 resistance in piglets. Int J Mol Sci (2014) 0.76
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature (2000) 32.30
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
The immunology of mucosal models of inflammation. Annu Rev Immunol (2001) 9.08
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol (1995) 4.81
Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem (1978) 4.61
Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int (1998) 4.31
Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature (1993) 4.19
Pathogenesis of cystic fibrosis. Lancet (1993) 3.34
Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science (1997) 2.38
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01
Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science (1994) 1.88
A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem (1987) 1.86
Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med (1991) 1.80
Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM (1996) 1.78
Cytokines in innate host defense in the lung. J Clin Invest (2002) 1.66
Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol (2000) 1.62
Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest (1999) 1.50
Functional domains of recombinant bactericidal/permeability increasing protein (rBPI23). J Biol Chem (1994) 1.41
Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate. J Clin Invest (1995) 1.29
An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci U S A (1997) 1.19
HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest (1999) 1.18
Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet (1999) 1.05
Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J Pediatr (1995) 1.05
The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes. J Biol Chem (2001) 1.03
Immunoglobulin G and its function in the human respiratory tract. Mayo Clin Proc (1988) 1.03
Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol (2002) 0.99
Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein. Implications in biological activity. J Biol Chem (1997) 0.99
A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett (1997) 0.95
Lipopolysaccharide (LPS) neutralizing peptides reveal a lipid A binding site of LPS binding protein. J Biol Chem (1995) 0.94
Inefficient protection of human TAP-deficient fibroblasts from autologous NK cell-mediated lysis by cytokines inducing HLA class I expression. Eur J Immunol (1999) 0.92
Plasma exudation in the airways: mechanisms and function. Eur Respir J (1991) 0.90
Fractional analysis of bronchoalveolar lavage fluid cytology in cystic fibrosis patients with normal lung function. Bronchoalveolar lavage for the evaluation of anti-inflammatory treatment (BEAT) study group. Eur Respir J (2000) 0.88
Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol (1999) 0.86
Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI. Pediatr Allergy Immunol (2000) 0.84
Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS Suppl (1995) 0.82
Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization. Pediatr Infect Dis J (2000) 0.80
Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA. J Immunol Methods (1997) 0.77
Pediatrics, surfactant, and cystic fibrosis in AJRCCM 2001. Am J Respir Crit Care Med (2002) 0.77
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem (1978) 4.61
Assembly of MHC class I molecules analyzed in vitro. Cell (1990) 3.77
Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med (1990) 3.37
Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med (1989) 3.33
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science (2000) 3.20
Separation and purification of a potent bactericidal/permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. J Biol Chem (1979) 3.15
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum (2000) 3.06
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest (1999) 3.00
Resistance of gram-negative bacteria to purified bactericidal leukocyte proteins: relation to binding and bacterial lipopolysaccharide structure. J Clin Invest (1980) 2.99
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol (2001) 2.69
The decision to breastfeed in the United States: does race matter? Pediatrics (2001) 2.67
Intracellular Ca(2+) dynamics and the stability of ventricular tachycardia. Biophys J (1999) 2.65
High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med (1998) 2.58
Seizure-associated brain injury in term newborns with perinatal asphyxia. Neurology (2002) 2.49
A reevaluation of the roles of the O2-dependent and O2-independent microbicidal systems of phagocytes. Rev Infect Dis (1983) 2.35
Race, family income, and low birth weight. Am J Epidemiol (1991) 2.30
Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med (1984) 2.29
Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J Biol Chem (1989) 2.29
Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol (1998) 2.24
Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol (1998) 2.21
Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20
High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun (1992) 2.17
Partial characterization and purification of a rabbit granulocyte factor that increases permeability of Escherichia coli. J Clin Invest (1975) 2.16
A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther (2013) 2.15
Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet (1986) 2.12
Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol (1987) 2.09
Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol (1996) 2.09
Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invest (1985) 2.05
Killing of gram-negative bacteria by polymorphonuclear leukocytes: role of an O2-independent bactericidal system. J Clin Invest (1982) 2.04
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
Improved differentiation between Churg-Strauss syndrome and Wegener's granulomatosis by an artificial neural network. Arthritis Rheum (2001) 2.00
Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci U S A (2001) 1.99
An evolving view of Saturn's dynamic rings. Science (2010) 1.99
Latex sensitization in health care workers and in the US general population. Am J Epidemiol (2001) 1.98
Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem (2001) 1.98
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) (2002) 1.98
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.95
Peptide-induced conformational change of the class I heavy chain. Nature (1991) 1.94
Role of charge and hydrophobic interactions in the action of the bactericidal/permeability-increasing protein of neutrophils on gram-negative bacteria. J Clin Invest (1983) 1.93
Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol (1999) 1.86
Nonclassical estrogen receptor alpha signaling mediates negative feedback in the female mouse reproductive axis. Proc Natl Acad Sci U S A (2007) 1.86
A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem (1987) 1.86
Early and discrete changes in permeability of Escherichia coli and certain other gram-negative bacteria during killing by granulocytes. J Exp Med (1974) 1.82
Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med (1991) 1.80
Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature (1992) 1.79
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol (1994) 1.76
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol (2000) 1.76
A simple method for measuring red cell deformability in models of the microcirculation. Blut (1973) 1.75
Prevention of pedestrian injuries to children: effectiveness of a school training program. Pediatrics (1991) 1.72
Intermittent dislocation flow in viscoplastic deformation. Nature (2001) 1.71
The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. J Immunol (1984) 1.67
Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood (1987) 1.66
Acceleration of wound healing by topical application of honey. An animal model. Am J Surg (1983) 1.66
Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nat Med (2001) 1.66
Source of bias in prenatal care utilization indices: implications for evaluating the Medicaid expansion. Am J Public Health (1991) 1.63
Pneumococcal septicemia in children with sickle cell anemia. Changing trend of survival. JAMA (1981) 1.62
Cyclosporin for acute dermatomyositis. Lancet (1984) 1.61
Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol (1994) 1.61
Heart rate variability. Frequency domain analysis. Cardiol Clin (1992) 1.60
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology (1990) 1.60
Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum (1999) 1.59
Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum (2000) 1.57
Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol (1990) 1.57
Introduction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species. Diabetologia (1998) 1.56
Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1978) 1.56
The potent anti-Staphylococcus aureus activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. J Clin Invest (1996) 1.54
Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest (1990) 1.52
Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) (2000) 1.52
Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol (2001) 1.51
Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum (1994) 1.51
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
Oxygen-independent intracellular and oxygen-dependent extracellular killing of Escherichia coli S15 by human polymorphonuclear leukocytes. J Clin Invest (1985) 1.50
Antimicrobial peptides of phagocytes and epithelia. Semin Hematol (1997) 1.50
Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol (1998) 1.49
Antibacterial 15-kDa protein isoforms (p15s) are members of a novel family of leukocyte proteins. J Biol Chem (1993) 1.48
The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide. Immunobiology (1993) 1.48
Environmental modulation of lipopolysaccharide chain length alters the sensitivity of Escherichia coli to the neutrophil bactericidal/permeability-increasing protein. Infect Immun (1986) 1.48
Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum (1992) 1.44
Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification. J Immunol (1989) 1.44
Selective block of urethral sphincter contraction using a modified Brindley electrode in sacral anterior root stimulation of the dog. Neurourol Urodyn (2002) 1.43
Isolation and characterization of a phospholipase A2 from an inflammatory exudate. J Lipid Res (1978) 1.42
Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. J Exp Med (1999) 1.42
Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum (1999) 1.42
Bidirectional movement of a nascent polypeptide across microsomal membranes reveals requirements for vectorial translocation of proteins. Cell (1992) 1.41
Head and neck manifestations of Wegener's granulomatosis. Rhinology (2006) 1.41
Detection of fungi in tissue sections by lectin histochemistry. Arch Pathol Lab Med (1988) 1.41
Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol (1998) 1.39
Reversible envelope effects during and after killing of Escherichia coli w by a highly-purified rabbit polymorpho-nuclear leukocyte fraction. Biochim Biophys Acta (1976) 1.39
[The risk profile of low-dose methotrexate in the therapy of chronic polyarthritis]. Dtsch Med Wochenschr (1992) 1.39
[SAPHO syndrome. Case description of 3 patients with acne conglobata and osteoarticular symptoms]. Hautarzt (1997) 1.38